Corticosteroids in Covid-19 pandemic have the potential to unearth hidden burden of strongyloidiasis | Zendy

Disha Gautam | Zendy; Ayush Gupta | Zendy; Adarsh Meher | Zendy; Farha Siddiqui | Zendy; Abhishek Singhai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Corticosteroids in Covid-19 pandemic have the potential to unearth hidden burden of strongyloidiasis

Author(s) -

Disha Gautam,

Ayush Gupta,

Adarsh Meher,

Farha Siddiqui,

Abhishek Singhai

Publication year - 2021

Publication title -

idcases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.319

H-Index - 13

ISSN - 2214-2509

DOI - 10.1016/j.idcr.2021.e01192

Subject(s) - medicine , strongyloidiasis , pandemic , strongyloides stercoralis , covid-19 , strongyloides , intensive care medicine , disease , immunology , infectious disease (medical specialty) , helminths

COVID-19 pandemic has posed formidable public health and clinical challenges to the entire humanity. A significant proportion of the COVID-19 patients have been provided immunosuppressive agents, particularly corticosteroids, as a part of management of moderate to severe COVID-19 disease. This has the drawback of development of strongyloides hyperinfection to disseminated infection in latent strongyloides infection patients. We are reporting the case of strongyloidiasis hyperinfection in a COVID-19 patient from a developing country, who initially received corticosteroid therapy for management of COVID-19, but later presented to hospital with non-specific, strongyloides related symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research